A Randomized, Open-label, Single-dose, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-115A and the Administration of AD-1151 for Healthy Subjects in Fasting State
Latest Information Update: 04 Apr 2025
At a glance
- Drugs AD 115A (Primary)
- Indications Gastric ulcer
- Focus Pharmacokinetics
- Sponsors Addpharma
- 04 Apr 2025 New trial record